A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who ...